Showing results (1-10 of 345) with videos related to
Sort By:
Pageof 35
Best Practice & Research. Clinical Haematology|June 3, 2004
Small-molecule direct antithrombins: argatrobanJawed Fareed, Walter P JeskeMethods in Molecular Biology (Clifton, N.J.)|July 10, 2010
Prasugrel: a novel platelet ADP P2Y(12) receptor antagonistShaker A Mousa, Walter P Jeske, Jawed FareedExpert Opinion on Investigational Drugs|July 19, 2005
Short- and long-acting synthetic pentasaccharides as antithrombotic agentsJeanine M Walenga, Walter P Jeske, Jawed FareedClinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 20, 2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonistShaker A Mousa, Walter P Jeske, Jawed FareedCurrent Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Factor Xa inhibitors: today and beyondJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.Future Cardiology|October 7, 2009
Update on the clinical applications of argatrobanJawed Fareed, Walter P Jeske, Debra A Hoppensteadt, et al.Journal of Thrombosis and Thrombolysis|January 12, 2012
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparinsMarc Cohen, Walter P Jeske, Jose C Nicolau, et al.Expert Review of Hematology|November 19, 2010
Pharmacology of argatrobanWalter P Jeske, Jawed Fareed, Debra A Hoppensteadt, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 14, 2013
Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight HeparinDebra A Hoppensteadt, Angel Gray, Walter P Jeske, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 10, 2009
Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic productsCafer Adiguzel, Walter P Jeske, Debra Hoppensteadt, et al.Pageof 35